IP Verse

Anti-Lypd3 Car T-Cell Therapy For The Treatment Of Cancer - EP3823992

The patent EP3823992 was granted to Duke University on Dec 13, 2023. The application was originally filed on Jul 19, 2019 under application number EP19838801A. The patent is currently recorded with a legal status of "Revoked".

EP3823992

DUKE UNIVERSITY
Application Number
EP19838801A
Filing Date
Jul 19, 2019
Status
Revoked
Jun 13, 2025
Grant Date
Dec 13, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HEMSATHSep 12, 2024KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE

Patent Citations (4) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2004071696
INTERNATIONAL-SEARCH-REPORTUS2017158775
INTERNATIONAL-SEARCH-REPORTWO2017064084
INTERNATIONAL-SEARCH-REPORTWO2019166877

Non-Patent Literature (NPL) Citations (4) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
SEARCH[ ] - Creative Biolabs, "Anti-LYPD3 (CBFYC-2933) h(CD28-CD3[zeta]) CAR, pCDCAR1 1", (20220329), URL: https://www.creative-biolabs.com/car-t/pdf/CAR-WFY6386.pdf, (20220329), XP055906236-
SEARCH- XINRU WEI ET AL, "PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells", ONCOIMMUNOLOGY, (20170206), vol. 6, no. 3, doi:10.1080/2162402X.2017.1284722, page e1284722, XP055603482 [A] 1-15 * page 12847222, column left, paragraph 4; figure 2; table 1 * * page 12847223; figure 5 *
SEARCH- J�RG WILLUDA ET AL, "Preclinical Antitumor Efficacy of BAY 1129980?a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody?Drug Conjugate for the Treatment of Non?Small Cell Lung Cancer", MOLECULAR CANCER THERAPEUTICS, US, (20170314), vol. 16, no. 5, doi:10.1158/1535-7163.MCT-16-0474, ISSN 1535-7163, pages 893 - 904, XP055465520 [A] 1-15 * page 896, column l, paragraph 1 - paragraph 2; figure 1 * * page 899 - page 901; figures 5,6 *
SEARCH- KESANG LI ET AL, "Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma", ONCOTARGET, (20151214), vol. 7, no. 3, doi:10.18632/oncotarget.6595, XP055641064 [A] 1-15 * page 2497; figure 1 * * page 2500 - page 2501; figure 5 * * page 2502; figure 7 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents